Insilico Medicine receives IND approval from FDA for ISM8969, an AI-empowered potential best-in-class NLRP3 inhibitor - EurekAlert!
Transforming Parkinson’s disease treatment, Insilico Medicine announces IND-enabling completion for AI-empowered oral NLRP3 inhibitor ISM8969 - EurekAlert!
An anti-complement homogeneous polysaccharide from Houttuynia cordata ameliorates acute pneumonia with H1N1 and MRSA coinfection through rectifying Treg/Th17 imbalance in the gut–lung axis and NLRP3 inflammasome activation - EurekAlert!
Mitochondrial GRIM19 loss induces liver fibrosis through NLRP3/IL33 activation via reactive oxygen species/NF-кB ... - EurekAlert
